Literature DB >> 8996174

Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes.

K Taguchi1, M Saitoh, S Sato, M Asano, M C Michel.   

Abstract

We have investigated the affinity and selectivity of tamsulosin and its metabolites, M1, M2, M3, M4 and AM1, at the tissue and the cloned alpha-1 adrenoceptor subtypes in the radioligand binding and the functional studies. In the radioligand binding studies, the compounds competed for [3H]prazosin binding to the rat liver and kidney alpha-1 adrenoceptors, with the rank order of potency tamsulosin approximately M4 > M1 > M2 approximately M3 > > AM1 with the latter having a negligible affinity. All compounds differentiated cloned alpha-1 adrenoceptor subtypes with the rank order of potency of alpha-1A > or = alpha-1D > alpha-1B, except for M4 which had the highest affinity for the alpha-1D adrenoceptor. The compounds also concentration-dependently antagonized phenylephrine-induced contractions in the rabbit aorta and prostate. The resulting apparent pA2 values were very similar to those at the cloned rat alpha-1A adrenoceptor. We conclude that most tamsulosin metabolites are high potency antagonists at the alpha-1 adrenoceptors and retain the alpha-1A over the alpha-1B adrenoceptor selectivity of tamsulosin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8996174

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Authors:  Gabriela Franco-Salinas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

Authors:  Joachim Troost; Shinji Tatami; Yasuhiro Tsuda; Michaela Mattheus; Ludwig Mehlburger; Martina Wein; Martin C Michel
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 4.  α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics.

Authors:  Shizuo Yamada; Yoshihiko Ito; Hideo Tsukada
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

5.  Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.

Authors:  K Taguchi; R F Schäfers; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 6.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Nandrolone treatment decreases the level of rat kidney alpha(1B)-adrenoceptors.

Authors:  Staffan Uhlén; Jonas Lindblom; Anna Kindlundh; Paul Mugisha; Fred Nyberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-12       Impact factor: 3.000

Review 8.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

9.  Measurement of tamsulosin in human serum by liquid chromatography-tandem mass spectrometry.

Authors:  Rita Upreti; Natalie Z M Homer; Gregorio Naredo; Diego F Cobice; Katherine A Hughes; Laurence H Stewart; Brian R Walker; Ruth Andrew
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-04-19       Impact factor: 3.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.